logo
logo
Search For Features
/
StocksStocks
Intraday BoosterIntraday Booster
Sector BoosterSector Booster
Stock ScreenerStock Screener
Market PulseMarket Pulse
ScreenersScreeners
MoreMore
prime iconGo Prime
My PlansMy Plans
Privacy PolicyPrivacy Policy
ContactContact
Refer & EarnRefer & Earn
ScreenersScreeners
Main
Stock ScreenerStock Screener
Create ScreenerCreate Screener
Explore ScreenersExplore Screeners
Community ScreenersCommunity Screeners
Trading Screeners
CandleSticks ScreenerCandleSticks Screener
Top Gainers & LosersTop Gainers & Losers
Opening Range BreakoutOpening Range Breakout
Stock Screener AIStock Screener AI
Stock Quality ScorecardStock Quality Scorecard
Overvalued StocksOvervalued StocksNew
Undervalued StocksUndervalued StocksNew
Technical Screeners
NR4 StocksNR4 Stocks
NR7 StocksNR7 Stocks
Previous Day High BreakoutPrevious Day High Breakout
Previous Day Low BreakoutPrevious Day Low Breakout
Previous Day Open BreakoutPrevious Day Open Breakout
Bullish Crossover StocksBullish Crossover Stocks
Bearish Crossover StocksBearish Crossover Stocks
High Volume ShockerHigh Volume Shocker
VWAP Breakout StocksVWAP Breakout Stocks
Range High BreakoutRange High Breakout
Range Low BreakoutRange Low Breakout
MoreMore
Markets
Global Market TodayGlobal Market Today
Global IndicesGlobal Indices
Indian IndicesIndian Indices
NIfty TodayNIfty Today
Smart Money
FII DII DataFII DII DataNew
FII BuyingFII Buying
NSE Insider TradingNSE Insider Trading
SLB Stocks DataSLB Stocks Data
Derivatives
FnO MovementsFnO Movements
NSE F&O Lot SizeNSE F&O Lot Size
Ban ListBan List
Analysis & Calendars
Technical DashboardTechnical Dashboard
Sector BoosterSector Booster
Sector AnalysisSector AnalysisNew
Result CalendarResult Calendar
Economic CalendarEconomic Calendar
Granules India Ltd

Granules India

Mid Cap•4,057 Employees•IPO 1995
Current Price
₹562.20
-24.55 (-4.18%)Updated
NSE :GRANULES
BSE :532482
Sector :Pharmaceuticals
Today's Range
554.95
₹562.20
indicator
585
52 Week Range
52W Low₹422.00
52W High₹627.00
₹562.20
indicator
Downside33.22%
Upside11.53%
chart iconChart

Price Chart

Compare with Peers

Historical Ratios

Track top 12 most important financial ratios

P/E Ratio: Price to Earnings - Most used valuation metric

Loading chart...

Analyzing Investment Quality

Processing 9 key metrics...

Key Metrics

Hover for details

Valuation

Market Cap
₹13,798.14 Cr
Market Cap
Total market value of company
P/E Ratio
25.30
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)
P/B Ratio
3.15
P/B Ratio
Price to Book Value. <3 may indicate undervaluation
EPS
₹22.48
EPS
Earnings Per Share. Higher and growing is positive

Profitability

ROE
7.34%
ROE
Return on Equity. >15% is good, >20% is excellent
ROCE
15.10%
ROCE
Return on Capital Employed. >15% is good
Net Margin
10.71%
Net Margin
Net profit as % of revenue. >10% is good
Operating Margin
-%
Operating Margin
Operating profit margin. >15% is good

Growth

EPS Growth (5Y)
9.47%
EPS Growth (5Y)
5-year EPS growth. >15% is strong
Revenue Growth (5Y)
11.52%
Revenue Growth (5Y)
5-year revenue growth. >10% is good
Qtr Sales Growth
2.56%
Qtr Sales Growth
Quarter-over-quarter sales growth
Qtr Profit Growth
-2.18%
Qtr Profit Growth
Quarter-over-quarter profit growth

Financial Health

Debt/Equity
0.39
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellent
Book Value
₹153.19
Book Value
Net asset value per share
Dividend Yield
0.26%
Dividend Yield
Annual dividend as % of price. >2% is good
Promoter Holding
38.80%
Promoter Holding
Promoter stake. >50% shows confidence
Good
Average
Needs Attention

SWOT Analysis

Strengths

4 points
  • •Granules India boasts a strong ROE of 13.9% and ROCE of 15.1%, indicating efficient profit generation from shareholder investments and capital employed. This highlights robust profitability and operational excellence, crucial for sustained growth.
  • •The company's March 2025 quarter net profit reached ₹152 crore, showcasing consistent growth and financial strength. This positive trend in profitability demonstrates resilience and potential for future growth, even amidst market volatility.

Weaknesses

5 points
  • •Promoter holding has decreased to 38.8% from over 40% previously, raising concerns about management commitment and potential future share dilutions. This decline warrants close monitoring for any further significant decreases in promoter stake.
  • •The company reported a quarterly profit variation of -2.18%, indicating a slight decline in recent profitability. This trend needs careful monitoring as sustained negative growth could impact future earnings and investor sentiment.

Opportunities

3 points
  • •Operating within the resilient Pharmaceuticals sector, Granules India can capitalize on increasing global healthcare expenditure and demand for essential medicines, driving future revenue growth and market expansion opportunities.
  • •As a NIFTY SMALLCAP 250 constituent, the company has significant potential for re-rating and accelerated growth compared to larger, more mature pharmaceutical players, attracting investors seeking high-growth opportunities.

Threats

4 points
  • •The highly competitive pharmaceutical landscape, with numerous established players, poses a significant threat to Granules India's market share and pricing power, potentially impacting future revenue and profit margins.
  • •Strict and evolving regulatory environments in key markets could lead to increased compliance costs, delays in product approvals, or product recalls, posing financial and reputational risks for the company.

Segment-wise Financial Analysis

Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...

Shareholding Pattern

Loading shareholding data...

Company Insider Trading Activity

No insider trading data available

Corporate Action

Company Announcements

Technical Analysis & Indicators

Standard pivot points - most widely used

Pivot Points (CLASSIC)

LevelPriceDistance% Change
R4₹639.92+₹77.72+13.82%
R3₹609.87+₹47.67+8.48%
R2₹597.43+₹35.23+6.27%
R1₹579.82+₹17.62+3.13%
PIVOT₹567.385.180.92%
CURRENT₹562.20--
S1₹489.67-₹72.53-12.90%
S2₹519.72-₹42.48-7.56%
S3₹537.33-₹24.87-4.42%
S4₹549.77-₹12.43-2.21%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: N/AP: N/ATC: N/A
R1
R2
R3
R4
indicator
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment

is trading CPR, indicating

● CPR Width

CPR is

● Opening Range

Day's range: ~

● Price Position

Trading Inside opening range

Delivery Volume Analysis & Trading Activity

Latest Volume
5.69L
(12 Mar 2026)
-7.2% vs avg
Delivery %
52.0%
(12 Mar 2026)
+0.4% vs avg
Avg Volume (20D)
6.13L
(12 Feb - 12 Mar)
20-day average
Avg Delivery %
51.6%
(12 Feb - 12 Mar)
Trend ↓
Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.

Peer Comparison & Industry Benchmarking

Quick Compare

Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Procter & Gamble Health Ltd
158.00 %
Highest Dividend Yield
Procter & Gamble Health Ltd
3.64 %

Peer Comparison

Company Name
ACUTAAS
Acutaas Chemicals Ltd
AETHER
Aether Industries Ltd
ALIVUS
Alivus Life Sciences Ltd
APLLTD
Alembic Pharmaceuticals Ltd
BLUEJET
Blue Jet Healthcare Ltd
CAPLIPOINT
Caplin Point Laboratories Ltd
COHANCE
Cohance Lifesciences Ltd
CONCORDBIO
Concord Biotech Ltd
JUBLPHARMA
Jubilant Pharmova Ltd
NATCOPHARM
Natco Pharma Ltd
NEULANDLAB
Neuland Laboratories Ltd
PGHL
Procter & Gamble Health Ltd
RUBICON
SANOFI
Sanofi India Ltd
SANOFICONR
Sanofi Consumer Healthcare India Ltd
SUNPHARMA
Sun Pharmaceutical Industries Ltd

About

GRANULES

Granules India Ltd

Granules India Limited is a prominent player in the pharmaceutical industry, specializing in the manufacture and sale of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates, and Finished Dosages (FDs). Their operations span both the domestic Indian market and international markets, demonstrating a significant global reach within the pharmaceutical supply chain. The company's diverse product portfolio caters to a wide range of therapeutic areas, showcasing its expertise across various medicinal applications.

A core component of Granules India's business is the production of APIs. These are the fundamental building blocks for many medications and Granules offers a substantial array, encompassing anti-retrovirals (used in HIV/AIDS treatment), anti-hypertensives (for blood pressure management), anti-histamines (treating allergies), anti-infectives (combatting infections), analgesics (pain relievers), anti-coagulants (blood thinners), anti-fibriotics (treating heart conditions), and platelet inhibitors (preventing blood clot formation). This broad spectrum highlights the company's comprehensive capabilities in API synthesis and manufacturing.

Beyond APIs, Granules India also offers finished dosage forms (FDs) including tablets, caplets, and press-fit capsules. These are supplied in various packaging formats such as bulk quantities, blister packs, and bottles, catering to different client needs and distribution channels. The company further distinguishes itself by manufacturing high potent products, typically requiring specialized handling and expertise, along with other products catering to the oncology (cancer treatment) sector. This demonstrates a commitment to serving high-demand and specialized pharmaceutical segments.

Granules India's commitment to innovation is evident in its provision of development and manufacturing solutions for peptides, peptide fragments, and amino acid derivatives. These complex molecules are increasingly important in modern medicine, and the company's investment in this area positions it at the forefront of pharmaceutical advancements. This diversification across various stages of pharmaceutical production, from basic APIs to complex finished dosages and specialized molecules, strengthens its position in the industry and allows for greater resilience against market fluctuations.

Established in 1984 and headquartered in Hyderabad, India, Granules India Limited has a long history of operation and a strong foothold in the global pharmaceutical landscape. The company's integrated approach, covering a wide range of pharmaceutical products and services, establishes it as a key supplier within the intricate and globally interconnected pharmaceutical supply chain.

COMPANY FACTS - GRANULES

Registered Address

2nd Floor, 3rd Block, My Home Hub Madhapur

Hyderabad

TELANGANA

IN

Tel: 914069043500

Website:https://granulesindia.com/

Investor Relations:http://www.granulesindia.com/investor.php
Company Details

Group: Pharmaceuticals, Biotechnology & Life Sciences

Sector: Health Care

Industry: Pharmaceuticals

Exchange: NATIONAL STOCK EXCHANGE OF INDIA

Employees: 4,057

IPO Date: 20/09/1995

MANAGEMENT - GRANULES

Dr. Krishna Chigurupati

Executive Chairman of the Board, Managing Director

Dr. Kandiraju Rao

Chief Executive Officer, Joint Managing Director, Executive Director

Mr. Mukesh Surana

Chief Financial Officer

Mr. Sanjay Kumar

President and Chief Strategy and Sustainability Officer

Mr. Ramraj Rangarajulu

President and Head - Formulations Operations

Mr. Atul Dhavle

Chief Human Resource Officer

Dr. Rajesh Kapoor

Senior Vice President, Global Head of Quality

Mr. G. N. Prashanth

Senior Vice President & Head Corporate Quality

Mr. Manikandan Ramalingam

Senior Vice President & Head Formulation R&D

Dr. P. V. Srinivas

Chief Technology Officer - Head of R&D

Ms. Chaitanya Tummala

Compliance Officer, Company Secretary

Ms. Priyanka Chigurupat

Executive Director, Executive Director of Granules Pharmaceuticals, Inc. & Granules USA, Inc.

Investor Questions Answered

Granules India Ltd (GRANULES) Stock FAQs

Get answers to the most common questions about Granules India Ltd stock price, fundamentals, financial metrics, and investment analysis

The current share price of Granules India Ltd (GRANULES) is ₹562.2. Today, the stock has declined by ₹24.55 (4.18%), trading in a range of ₹554.95 to ₹585. The stock opened at ₹585 with a trading volume of 4,32,376 shares.
Granules India Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹13,798.14 crores, P/E ratio of 25.30, ROE of 7.34%, and ROCE of 15.10%. The dividend yield stands at 0.26%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Granules India Ltd (GRANULES) is ₹627, while the 52-week low is ₹422. Currently trading at ₹562.2, the stock is 68.4% away from its 52-week low and 10.3% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Granules India Ltd stock at ₹562.2 depends on multiple factors. The stock is currently trading with a P/E ratio of 25.30 and P/B ratio of N/A. Today's performance shows a loss of 4.18%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Granules India Ltd offers a dividend yield of 0.26%, which means for every ₹100 invested at the current price of ₹562.2, you can expect to receive approximately ₹0.26 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Granules India Ltd's key financial metrics include: P/E Ratio: 25.30, P/B Ratio: N/A, ROE: 7.34%, ROCE: 15.10%, Dividend Yield: 0.26%, EPS: ₹22.48, Book Value: ₹153.19, Debt-to-Equity: 0.39, and Current Ratio: N/A. The company's market cap stands at ₹13,798.14 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Granules India Ltd stock opened at ₹585 and is currently trading at ₹562.2, showing a decline of ₹24.55 (4.18%). The intraday high is ₹585 and low is ₹554.95. The trading volume stands at 4,32,376 shares, indicating moderate market participation today.
Granules India Ltd has a Price-to-Earnings (P/E) ratio of 25.30, which means investors are willing to pay ₹25.30 for every ₹1 of earnings. With an EPS of ₹22.48, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Granules India Ltd has a market capitalization of ₹13,798.14 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹562.2) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Granules India Ltd has a book value of ₹153.19 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹562.2, which is 267.0% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Granules India Ltd has a Return on Equity (ROE) of 7.34% and Return on Capital Employed (ROCE) of 15.10%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Granules India Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Granules India Ltd has a debt-to-equity ratio of 0.39, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Granules India Ltd has an Earnings Per Share (EPS) of ₹22.48, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹562.2 and P/E ratio of 25.30, investors are paying 25.30 times the annual earnings per share. This moderate EPS suggests decent earnings generation. Track EPS growth over quarters to assess earnings momentum.
Granules India Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Granules India Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Granules India Ltd stock, consider: 1) Fundamental Analysis - Review P/E (25.30), ROE (7.34%), debt-to-equity (0.39), and growth rates. 2) Technical Analysis - Check 52-week range (₹422.00 - ₹627.00), moving averages, and chart patterns. 3) Valuation - Compare current price (₹562.20) with book value (₹153.19) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Granules India Ltd share is ₹1.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹562.2 is 56120x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Granules India Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹422.00 - ₹627.00). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.39 indicates leverage. 4) Liquidity Risk - Based on trading volume of 4,32,376 shares. 5) Valuation Risk - P/E of 25.30 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Granules India Ltd operates in the industry with key metrics: P/E ratio of 25.30, ROE of 7.34%, market cap of ₹13,798.14 crores, and dividend yield of 0.26%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.39), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Granules India Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹562.2, with a 52-week range of ₹422.00 to ₹627.00. Based on fundamentals like P/E (25.30), ROE (7.34%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Granules India Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹562.20. 2) Fundamental Deterioration - Declining ROE (currently 7.34%), increasing debt (D/E: 0.39), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Granules India Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.26%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.